Canonical Pathways,1vsAll,2vsAll,3vsAll,4vsAll,5vsAll,6vsAll
14-3-3-mediated Signaling,1,0,0.577,2.744,2.694,-2.5
1D-myo-inositol Hexakisphosphate Biosynthesis II (Mammalian),0,0,0,-1.89,-0.447,0
3-phosphoinositide Biosynthesis,1.897,0,2.558,0.866,1.982,-1.528
3-phosphoinositide Degradation,0.816,0,3.771,0.152,1.151,-1.069
4-1BB Signaling in T Lymphocytes,0,0,0,-0.333,-0.378,-1.89
4-aminobutyrate Degradation I,0,0,0,0,0,0
ABRA Signaling Pathway,0,1,3.536,-0.577,-0.392,-2.887
Acetate Conversion to Acetyl-CoA,0,0,0,0,0,0
Acetylcholine Receptor Signaling Pathway,2.668,1.342,2.6,1.313,0.289,-1.877
Actin Cytoskeleton Signaling,3.153,0.447,2.556,1.953,-0.137,-3.674
Actin Nucleation by ARP-WASP Complex,1.89,0,0.707,2.558,1.633,-1.897
Activation of gene expression by SREBF (SREBP),0,0,-1.414,-0.905,1.5,0
Activation of IRF by Cytosolic Pattern Recognition Receptors,0,0,0.816,1.387,1,-2.121
Activation of kainate receptors upon glutamate binding,0,0,1,0.632,-0.905,0
Activation of Matrix Metalloproteinases,3,0,2.53,0.333,-2.111,-2.646
Activation of NMDA receptors and postsynaptic events,0,0,1.342,2,1.213,-1.633
Activation of the pre-replicative complex,2.449,0,0,2.121,1.342,0
Activin Inhibin Signaling Pathway,2.294,-0.816,1.808,2.032,1.432,-3.55
Acute Myeloid Leukemia Signaling,0,0,-0.333,2.117,1.257,-0.943
Acute Phase Response Signaling,0,0,0,2.714,2.03,-1.147
Adenine and Adenosine Salvage III,0,0,0,0,0,0
Adenosine Nucleotides Degradation II,0,0,0,-0.447,0,0
Adipogenesis pathway,0,-1,-0.471,0.539,-0.16,2.111
Adrenergic Receptor Signaling Pathway (Enhanced),0.943,1.414,1.633,-0.14,-0.309,-0.426
Adrenomedullin signaling pathway,3.5,0,0.626,2.06,0.405,-2.449
Agranulocyte Adhesion and Diapedesis,0,0,0,0,0,0
Agrin Interactions at Neuromuscular Junction,0.816,0,1.897,0.688,1.291,-1.89
Airway Inflammation in Asthma,0,0,0,0,0,0
Airway Pathology in Chronic Obstructive Pulmonary Disease,0,0,0,0,0,0
Aldosterone Signaling in Epithelial Cells,2.828,0,1.069,1.061,0.962,-2.138
Amino acids regulate mTORC1,0,0,1.342,-1.414,0.535,0
AMPK Signaling,2.53,0,0.218,1.508,1.206,-0.728
Amyloid Processing,0,0,2.236,-0.302,-1.342,0
Amyotrophic Lateral Sclerosis Signaling,2.646,0,1.213,-0.378,-1,-2.309
Androgen Biosynthesis,0,2,0,-2,0,0
Androgen Signaling,0.816,0,2.449,0.688,0,-1.667
Angiopoietin Signaling,1,0,1.134,1.606,0.209,-0.333
Antioxidant Action of Vitamin C,-3.464,0,-2.121,-0.426,1.091,4
Antiproliferative Role of Somatostatin Receptor 2,2,0,-0.378,2.828,2,-1.265
Apelin Adipocyte Signaling Pathway,-1,0,0.378,0.6,1.414,0
Apelin Cardiac Fibroblast Signaling Pathway,0,0,-1,0.378,0,2
Apelin Cardiomyocyte Signaling Pathway,2.333,0,1.789,1.372,0.365,-2.5
Apelin Endothelial Signaling Pathway,1.732,0,0,3.781,2.53,-1.706
Apelin Liver Signaling Pathway,0,0,2.449,-0.707,-1.134,-2.646
Apelin Muscle Signaling Pathway,0,0,0,1.633,1.633,0
Apelin Pancreas Signaling Pathway,0,0,-1.89,2,2.357,0.632
Apoptosis Signaling,0,0,1.633,-2.921,-0.784,-0.258
April Mediated Signaling,0,0,1.633,-0.333,0.905,-2.333
Aryl Hydrocarbon Receptor Signaling,0.302,0,2.111,0.447,1.89,-0.632
Asparagine N-linked glycosylation,0,0,2,-0.302,1.633,1
Aspirin ADME,0,0,0,0,0,2
Assembly and cell surface presentation of NMDA receptors,2,0,1.342,0,-0.905,-1.134
Assembly of collagen fibrils and other multimeric structures,4.899,-1.134,4.359,-0.447,-3.5,-4.796
Atherosclerosis Signaling,0,0,0,0,0,0
ATM Signaling,0,0,1,-1.46,-0.655,-0.816
Atorvastatin ADME,0,0,0,0,0,2.236
Autism Signaling Pathway,2.858,-0.632,2.949,1.132,1.501,-3.086
Autophagy,-0.832,0,1.877,0.258,0.508,-0.626
Axonal Guidance Signaling,0,0,0,0,0,0
B Cell Activating Factor Signaling,0,0,2,-0.707,0.632,-2.828
Basal Cell Carcinoma Signaling,0,0,2.714,-1.155,-0.277,-1.414
Beta-catenin independent WNT signaling,2.828,0,2.309,0.816,-0.209,-3.464
BEX2 Signaling Pathway,0,0,2.138,-0.218,-1.528,-1.732
Bladder Cancer Signaling,0,0,2.121,1.155,2.111,-0.447
BMP signaling pathway,0,0,0.816,3,2.2,-1.134
Branched-chain amino acid catabolism,0,0,-1,1.342,1.342,2.236
Branched-chain α-keto acid Dehydrogenase Complex,0,0,0,0,0,0
Breast Cancer Regulation by Stathmin1,7.407,-2.524,1.668,5.544,1.362,-5.58
Bupropion Degradation,0,0,0,1.342,0,2.236
B-WICH complex positively regulates rRNA expression,0,0,2.236,-0.832,0.775,0
Cachexia Signaling Pathway,1.8,-1.155,3.683,1.325,0.775,-2.654
Calcium Signaling,2.121,0.816,2.357,0.324,0.378,-1.89
Calcium Transport I,0,0,0,0,0,0
cAMP-mediated signaling,4.041,-0.447,0.962,3.077,1.633,-1.528
Cancer Drug Resistance by Drug Efflux,0,0,0.378,2.324,2.183,-1
Carboxyterminal post-translational modifications of tubulin,2,0,0,-1.342,-1.633,-2.646
Cardiac conduction,1.414,0,2.502,-0.507,-0.73,-0.632
Cardiac Hypertrophy Signaling,2.5,0,3.286,1.313,0.516,-2.556
Cardiac Hypertrophy Signaling (Enhanced),5.246,-2.236,3.395,3.692,2.594,-4.185
Cardiac β-adrenergic Signaling,2.333,0,-0.302,0.707,0.756,-0.302
Cardiomyocyte Differentiation via BMP Receptors,0,0,0,0,2,0
Cargo concentration in the ER,0,0,0,2.183,2.53,0
Catecholamine Biosynthesis,0,0,0,0,0,0
Caveolar-mediated Endocytosis Signaling,0,0,0,0,0,0
CCR3 Signaling in Eosinophils,3,0,0.535,2.502,1,-2.5
CD27 Signaling in Lymphocytes,0,0,2.236,-1.387,-1.291,-1.897
CD40 Signaling,1.134,0,0.302,1.342,0.943,-1.807
CDK5 Signaling,0,0,2.496,0.928,-0.392,-1.069
CDP-diacylglycerol Biosynthesis I,0,0,0,0.378,0.707,0
CDX Gastrointestinal Cancer Signaling Pathway,-1.342,1,-0.686,-1.131,-0.493,2.646
Cell Cycle Checkpoints,1.897,-1.414,4.583,2,5.17,-3.638
Cell Cycle Control of Chromosomal Replication,2.449,0,2,0.229,0.832,0
Cell Cycle: G1/S Checkpoint Regulation,0,0,-1,0.632,-0.302,2.121
Cell Cycle: G2/M DNA Damage Checkpoint Regulation,0,0,0.447,0.277,-0.333,0
Cell junction organization,3.051,-1,3.3,0,-1.095,-0.632
Cell surface interactions at the vascular wall,4.811,-2.828,1.225,4.907,0.762,-4.802
Cellular Effects of Sildenafil (Viagra),0,0,0,0,0,0
Cellular hexose transport,0,0,0.447,-0.333,0,0
Ceramide Biosynthesis,0,0,0,1.342,0,0
Ceramide Degradation,0,0,0,2,0,0
Ceramide Signaling,-1.134,0,3.051,-0.192,-0.756,-1
CGAS-STING Signaling Pathway,2.111,-1.342,3.207,1.521,0.853,-4.025
Chemokine Signaling,1.414,0,0.707,2.746,1.043,-1.807
Cholecystokinin/Gastrin-mediated Signaling,0.632,0,1.414,2.401,1.915,-2.5
Cholesterol biosynthesis,0,2,-1.342,-1,2.121,0
Cholesterol Biosynthesis I,0,0,0,0,2,0
"Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol)",0,0,0,0,2,0
Cholesterol Biosynthesis III (via Desmosterol),0,0,0,0,2,0
Chondroitin Sulfate Biosynthesis,1.667,0,1,0.229,0.333,-0.816
Chondroitin Sulfate Biosynthesis (Late Stages),2.121,0,0,0.775,0.707,-0.816
Chronic Myeloid Leukemia Signaling,3.411,-0.378,3.92,0.465,-0.115,-5.308
Cilium Assembly,1.633,1,3.153,-1.549,2.188,-1.414
Circadian Clock,0.816,0,0.707,0.894,1.877,0
Circadian Rhythm Signaling,0,0,0,0,0,0
Citrulline-Nitric Oxide Cycle,0,0,0,0,0,0
Class A/1 (Rhodopsin-like receptors),5.284,-1.414,2.626,4.6,0.149,-5.477
Class B/2 (Secretin family receptors),3.162,0.447,3,0.378,-1.606,-3.162
Class I MHC mediated antigen processing and presentation,3.3,0,0.365,2.887,4.159,-0.784
Class I peroxisomal membrane protein import,0,0,0,0.378,2.121,0
Clathrin-mediated endocytosis,1.134,0,1.667,1.808,0.73,-2
Clathrin-mediated Endocytosis Signaling,0,0,0,0,0,0
CLEAR Signaling Pathway,-1.606,0.333,1,-1.478,-1.359,-0.426
CNTF Signaling,0,0,-1,3.266,2.887,-1.265
Coagulation System,0.816,0,-0.905,1.604,0.447,-1.414
Collagen biosynthesis and modifying enzymes,3.742,0,3.578,-0.853,-3.13,-4.583
Collagen chain trimerization,3.742,0,3.638,-0.775,-3.207,-4.243
Collagen degradation,4.243,-1.342,4.359,-0.218,-3.153,-4.69
Colorectal Cancer Metastasis Signaling,3.128,-1.633,3.569,2.91,0.62,-4.629
Complement System,1,0,0,0.333,-0.447,0
COPII-mediated vesicle transport,1.342,0,-0.378,1.877,2.4,1
Corticotropin Releasing Hormone Signaling,1,1.342,1.069,2.53,1.461,-1.069
Costimulation by the CD28 family,2.236,0,-0.378,2.711,1.155,-2.84
CREB Signaling in Neurons,8.05,-2.357,0.853,5.702,0.53,-5.893
Crosstalk between Dendritic Cells and Natural Killer Cells,2.714,0,0,4.264,-0.258,-4
CXCR4 Signaling,1.155,0,2.065,3.086,1.48,-2.2
Cyclins and Cell Cycle Regulation,0,0,0,-0.632,0.905,-0.333
Cysteine Biosynthesis/Homocysteine Degradation,0,0,0,0,0,0
Cytoprotection by HMOX1,0,0,1.89,-0.655,-0.277,0
Cytosolic iron-sulfur cluster assembly,0,0,0,0,-1.633,0
DAG and IP3 signaling,0,0,0,2.309,0,-2.236
DAP12 interactions,2.646,0,0,3.9,1.414,-3.162
DDX58/IFIH1-mediated induction of interferon-alpha/beta,0,0,2,2.324,2.236,-0.816
Degradation of the extracellular matrix,4.123,-1.633,2.673,1.279,-2.496,-3
Dermatan Sulfate Biosynthesis,1.667,0,1,0.229,0,-0.816
Dermatan Sulfate Biosynthesis (Late Stages),2.121,0,0,0.577,0.816,-0.816
Detoxification of Reactive Oxygen Species,2.236,0,1,0.832,0,-1.89
DHCR24 Signaling Pathway,1.414,1.342,0.577,1.474,2,0.209
Dilated Cardiomyopathy Signaling Pathway,2,-2,-2.711,0.667,1.225,-0.447
Dissolution of Fibrin Clot,0,0,0,0,0,-2.236
"D-myo-inositol (1,3,4)-trisphosphate Biosynthesis",0,0,0,-1.134,0,0
"D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis",0.816,0,3.5,0.316,1.521,-1.069
"D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis",0.816,0,3.5,0.316,1.521,-1.069
D-myo-inositol-5-phosphate Metabolism,1.414,0,3.638,0.149,0.973,-1.5
DNA Damage Reversal,0,0,0,-0.447,0,0
Docosahexaenoic Acid (DHA) Signaling,4.796,-1.508,1.219,2.525,1.068,-2.335
Dopamine-DARPP32 Feedback in cAMP Signaling,2.53,0,1.265,1.131,0.169,-2.887
E3 ubiquitin ligases ubiquitinate target proteins,0,0,0,1.941,2.84,0
Effects of PIP2 hydrolysis,0,0,0,0.333,0,-2.449
EGF Signaling,0.816,0,0,1.886,2.357,-2.111
EGR2 and SOX10-mediated initiation of Schwann cell myelination,0,0,-0.378,1.89,1.265,-0.447
Eicosanoid Signaling,2.449,0,1.342,2.121,0,-2.236
Elastic fibre formation,3.873,-2.646,2.683,2.138,-1.698,-4.123
"Electron transport, ATP synthesis, and heat production by uncoupling proteins",0,2,3,-4.743,-0.243,1.89
Endocannabinoid Cancer Inhibition Pathway,-1.265,0,-0.471,-1.605,-0.469,3.128
Endocannabinoid Developing Neuron Pathway,1.414,0,0,1.667,1.257,-0.943
Endocannabinoid Neuronal Synapse Pathway,2.673,-1,1.897,-0.649,-1.029,-1.807
Endometrial Cancer Signaling,0,0,-0.816,3.153,2.357,-1.265
Endosomal Sorting Complex Required For Transport (ESCRT),0,0,0,0.577,0.302,0
Endothelin-1 Signaling,3.545,0,1.964,2.405,1.069,-3.413
Energy dependent regulation of mTOR by LKB1-AMPK,0,0,0,-0.302,0.632,0
eNOS Signaling,2.887,0,1.213,2,1.225,-2
EPH-Ephrin signaling,2.449,0,2.121,1.257,-0.816,-2.111
Ephrin A Signaling,0,0,0,0,0,0
Ephrin B Signaling,2.236,0,0,2.828,-1.069,-2.53
Ephrin Receptor Signaling,3.464,-1,1.069,3.709,1.732,-1.342
Epithelial Adherens Junction Signaling,0,0.378,0.447,0.146,-0.687,-0.853
ERB2-ERBB3 Signaling,2,0,0,2.524,2.683,-1.732
ERBB Signaling,0,0,1.155,2.711,2.746,-2.138
ERBB4 Signaling,1.342,0,-0.378,3.441,2.982,-1.732
ERK/MAPK Signaling,3.357,0,1.134,2.582,0.849,-3
ERK5 Signaling,1,0,2.121,3.138,3.157,-1.134
Erythropoietin Signaling Pathway,0,1.414,0.392,2.832,1.342,-1.134
Estrogen Biosynthesis,0,2.236,0,0,0.816,2.646
Estrogen Receptor Signaling,3.922,-1.414,3.938,1.238,0.704,-3.569
Estrogen-Dependent Breast Cancer Signaling,0.447,0,-0.333,3.5,2.524,-1.732
Ethanol Degradation II,0,0,0,1.342,0,0
Extracellular matrix organization,5.477,-1.941,5.209,0.649,-2.043,-5.099
Extra-nuclear estrogen signaling,0.816,0,0.905,3,2.065,-1.633
Extrinsic Prothrombin Activation Pathway,0,0,0,-0.447,0,0
Factors involved in megakaryocyte development and platelet production,1.342,0,3.207,0.816,-1.633,-2.646
Factors Promoting Cardiogenesis in Vertebrates,2.828,0,2.84,1.667,1.441,-3.3
FAK Signaling,9.217,-2.4,1.473,7.194,0.949,-7.06
Fanconi Anemia Pathway,0,0,1.633,-1.387,0.577,0
FAT10 Cancer Signaling Pathway,1,0,0,1.508,0.577,-1.897
Fatty acyl-CoA biosynthesis,0,0,0,-0.447,0.632,0
Fc Epsilon RI Signaling,3.162,0,0.832,3.703,1.826,-3.411
Fcgamma receptor (FCGR) dependent phagocytosis,3.162,0,0.707,4.849,0.5,-3.771
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes,4,0,0.832,2.466,0.447,-3.71
Ferroptosis Signaling Pathway,2,-1.342,1.265,2.828,1.414,-0.333
FGF Signaling,1.342,0,0.258,2.2,2.887,-1
FLT3 Signaling,0,0,0,2.673,1.897,-2.646
FLT3 Signaling in Hematopoietic Progenitor Cells,2,0,0.333,3.182,3.157,-1.941
fMLP Signaling in Neutrophils,3.162,0,0,4.333,1.859,-2.4
Formation of Fibrin Clot (Clotting Cascade),2.236,0,-0.302,2.673,0.816,0
Formation of WDR5-containing histone-modifying complexes,0,0,2,-2.138,-0.577,0
FXR/RXR Activation,-0.905,-0.333,-0.471,-0.849,-1.219,0.209
G alpha (12/13) signalling events,2.496,0,2.84,-0.343,-1.225,-2.887
G alpha (i) signalling events,4.802,-1.213,2.412,4.333,-0.617,-4.707
G alpha (q) signalling events,3.545,-2.236,1.177,3.576,0.667,-4.123
G alpha (s) signalling events,3.051,0.378,3.273,2.03,-0.898,-3.3
G alpha (z) signalling events,2.236,0,1.633,2.324,-0.302,-2.333
G Beta Gamma Signaling,1.89,0,2.333,3.452,1.616,-2.138
GABA Receptor Signaling,0,0,0,0,0,0
GABAergic Receptor Signaling Pathway (Enhanced),-0.302,-0.905,0.894,1.093,0.87,1.604
GADD45 Signaling,0.447,0,0.816,-2.309,0.535,1.155
"Gamma carboxylation, hypusine formation and arylsulfatase activation",0,0,0.816,0.535,0.577,0
Gap Junction Signaling,0,0,0,0,0,0
GDNF Family Ligand-Receptor Interactions,1,0,0.632,2.711,1.095,-2.324
GDP-glucose Biosynthesis,1,0,0,0,0,0
GDP-L-fucose Biosynthesis II (from L-fucose),0,0,0,0,0,0
Generic Transcription Pathway,3.3,1,3.307,-4.419,3.074,0.243
Germ Cell-Sertoli Cell Junction Signaling,0,0,0,0,0,0
Glioblastoma Multiforme Signaling,2.53,0,2.132,1.581,1.543,-3.272
Glioma Invasiveness Signaling,2.53,0,0.302,3.545,2.132,-2.065
Glioma Signaling,2,0,-0.707,3.024,2.711,-1.604
Glucocorticoid Biosynthesis,0,0,0,0,0,0
Glucocorticoid Receptor Signaling,0,0,0,0,0,0
Glucose and Glucose-1-phosphate Degradation,1,0,0,0,0,0
Glutamate Degradation III (via 4-aminobutyrate),0,0,0,0,0,0
Glutamate Receptor Signaling,0,0,0,-0.333,-1.633,0
Glutaminergic Receptor Signaling Pathway (Enhanced),4.747,-0.832,2.412,0.834,0.216,-3.781
Glycerophospholipid biosynthesis,2.828,0,2.668,-0.2,0,-1.508
Glycine Degradation (Creatine Biosynthesis),0,0,0,0,0,0
Glycoaminoglycan-protein Linkage Region Biosynthesis,0,0,0,-1,0,0
Glycogen Biosynthesis II (from UDP-D-Glucose),0,0,0,0.447,0,0
Glycogen metabolism,0,0,1,-0.333,0,0
Glycosaminoglycan metabolism,3.207,0,1.807,2.268,-0.6,-1.941
Glyoxylate metabolism and glycine degradation,0,0,0,0.447,0,2.236
GM-CSF Signaling,2.449,0,-0.816,3.922,2.837,-1.732
GNRH Signaling,1,0,3.5,1.474,0.745,-1.789
GP1b-IX-V activation signalling,2.236,0,1.633,0,-0.447,-2
GP6 Signaling Pathway,5.196,0,3.402,2.214,-1.715,-5.396
GPCR-Mediated Integration of Enteroendocrine Signaling Exemplified by an L Cell,0.378,0,0.378,0,-0.229,-0.333
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells,2.887,0,2.333,0.343,-1.134,-2.84
GPER1 signaling,0,0,0.447,2.183,0.277,-1.342
G-protein beta:gamma signalling,2.236,0,0,2.111,-0.333,-2.236
G-Protein Coupled Receptor Signaling,6.533,-1.147,1.628,5.026,0.152,-5.607
GPVI-mediated activation cascade,2.53,0,1.134,2.84,0.333,-3.317
Granulocyte Adhesion and Diapedesis,0,0,0,0,0,0
Granzyme A Signaling,0,-1,-2.121,4.041,2.111,-2.236
Growth hormone receptor signaling,0,0,0.447,1.897,1.134,0
Growth Hormone Signaling,1.342,0,-1.897,2.449,1.8,-2.111
Gustation Pathway,2.837,-0.333,3.212,-1.131,-0.309,-1.886
Gα12/13 Signaling,1.387,0,0.408,2.214,1,-2.236
Gαi Signaling,3.051,0,0.535,3.244,2.043,-0.832
Gαq Signaling,2.828,0,0.258,2.654,-0.156,-3.8
Gαs Signaling,2.121,0,2.111,0.87,-1.5,-1.732
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),2.236,0,2.236,-1,1.826,0
Hematopoiesis from Multipotent Stem Cells,0,0,0,0,0,0
Heme signaling,0.447,0,0,-0.5,-0.426,0
Heparan Sulfate Biosynthesis,1.667,0,1.633,-0.447,0.277,-0.378
Hepatic Cholestasis,2.324,-0.447,1.4,1.432,0.289,-3.413
Hepatic Fibrosis / Hepatic Stellate Cell Activation,0,0,0,0,0,0
Hepatic Fibrosis Signaling Pathway,4.459,-0.333,2.954,2.098,1.65,-4.636
HER-2 Signaling in Breast Cancer,2.183,-0.447,0.577,4.826,2.38,-3.651
Hereditary Breast Cancer Signaling,0,0,0,0,0,0
HGF Signaling,1.265,0,0.5,2.611,3,-1.886
HIF1α Signaling,3.307,-0.707,1.715,3.299,0.816,-2.874
HIPPO signaling,0,0,0,-1.5,-0.728,0.378
HMGB1 Signaling,1.291,0,1.886,1.826,1.061,-3.272
HOTAIR Regulatory Pathway,4.359,-2,2.887,1.461,-0.333,-4.041
Human Embryonic Stem Cell Pluripotency,3.873,0,3.307,2.177,1.953,-3.053
Huntington's Disease Signaling,1.897,0,0.5,2.667,0.343,-1.069
Hypoxia Signaling in the Cardiovascular System,-0.447,0,2,0,0,0
ID1 Signaling Pathway,2.828,0.816,1.947,2.077,1.291,-2.92
IGF-1 Signaling,0,0,-0.577,2.401,2.401,-0.632
IL-1 Signaling,0,0,1.633,0.535,0.5,-1.667
IL-10 Signaling,0,0,0.943,1.021,-0.18,-0.209
IL-12 Signaling and Production in Macrophages,0.928,1.342,1.372,0.12,-1.361,-3.317
IL-13 Signaling Pathway,1.134,0,-0.688,2.335,2.837,-2.5
IL-15 Production,3.578,0,2.858,0,-1.915,-3.674
IL-17 Signaling,2.138,-1.414,4.226,1.982,1.915,-3.922
IL-17A Signaling in Airway Cells,1.342,0,0.577,0.943,1.414,-1.387
IL-17A Signaling in Fibroblasts,1.069,0,2.837,1.732,0,-3.441
IL-17A Signaling in Gastric Cells,0,0,2.236,-1,0,0
IL-2 Signaling,1.89,0,-0.333,3.71,2.4,-2.324
IL-23 Signaling Pathway,1,0,-1,2.668,2.138,-1.134
IL-3 Signaling,1.414,0,0,4.082,3.545,-2.324
IL-33 Signaling Pathway,1.789,0,1.569,3.317,1.093,-2.449
IL-6 Signaling,0.707,0,0.392,2.333,2.466,-2.132
IL-7 Signaling Pathway,2,0,-0.905,2.711,2.524,-2.324
IL-8 Signaling,4.49,-0.816,1.061,4.41,1,-4.743
IL-9 Signaling,1,0,-1.414,2.309,1.155,-2.53
ILK Signaling,0.832,0.816,3.333,1.155,0.149,-2.041
Immunogenic Cell Death Signaling Pathway,1,0,1.633,2.043,-0.243,-4
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,4.796,-0.816,1.414,5.571,-1.414,-5.667
Induction of Apoptosis by HIV1,0,0,1.342,-1.606,-1.069,-1.897
Inflammasome pathway,2,0,0,2.333,-0.447,-2.333
Inhibition of Angiogenesis by TSP1,0.816,0,-0.378,0,0.378,-1
Inhibition of Matrix Metalloproteases,-2.53,0.816,-2.121,0.707,0.333,0.707
iNOS Signaling,0,0,1.633,0.277,0.577,-2.828
Insulin processing,0,0,0,2.309,2.309,0
Insulin Receptor Signaling,0.447,0,-0.577,2.111,2.967,-0.302
Insulin Secretion Signaling Pathway,2.84,0,1.671,2.065,1.692,-3.528
Integration of energy metabolism,2.333,0,1.732,1.177,0,-1.732
Integrin cell surface interactions,5.831,-1.508,4.131,1.521,-2.646,-5.196
Integrin Signaling,4.379,-0.333,3.212,1.89,1.664,-3.286
Integrin signaling,2.236,0,0,2.333,-0.333,-2
Interferon gamma signaling,3.317,0,2.673,1.671,-0.775,-3.606
Interleukin-1 processing,0,0,0,0,0,0
Interleukin-10 signaling,2.496,0,2.309,3.638,0,-3.742
Interleukin-12 family signaling,0,0,1.342,1.155,0,0
Interleukin-15 signaling,0,0,0,1.342,-0.447,-2
Interleukin-2 family signaling,3,0,1,2.065,0.905,-3.873
"Interleukin-3, Interleukin-5 and GM-CSF signaling",2.828,0,0,2.837,1.732,-3.051
Interleukin-4 and Interleukin-13 signaling,3,0,2.268,3.507,0,-2.887
Interleukin-6 family signaling,0,0,1.667,1.155,1.414,-1.342
Interleukin-7 signaling,0,0,0,1,0.707,-1
Interleukin-9 signaling,0,0,0,1,0,-2
Intestinal absorption,0,0,0,0,0,0
Intra-Golgi and retrograde Golgi-to-ER traffic,2.828,1.633,2.828,1.905,2.219,-2.524
Intrinsic Prothrombin Activation Pathway,2.236,0,1.155,0.535,-0.707,-1.134
Ion channel transport,3.153,0.447,3.286,-1.483,0.295,-2.828
Iron homeostasis signaling pathway,0,0,0,0,0,0
ISG15 antiviral mechanism,0,0,1,1.886,2.858,0
ISGylation Signaling Pathway,2.333,0,1.604,0.73,0.378,-2.673
JAK/STAT Signaling,0,0,0.277,2.043,1.616,-1.941
Kinesins,0,2,2.828,0,-1.414,-3.464
Kinetochore Metaphase Signaling Pathway,0,0,0.577,1.347,1.134,-0.707
L1CAM interactions,3.441,-1.265,2.985,0.898,-0.707,-3.357
Late endosomal microautophagy,0,0,2,0.577,-0.707,0
Leptin Signaling in Obesity,0,0,-1.89,2.673,2.138,-0.378
Leukocyte Extravasation Signaling,4.747,-2,0.962,4.036,1.938,-4.629
Leukotriene Biosynthesis,0,0,0,0,0,0
LGI-ADAM interactions,0,0,2,-2.236,-2.236,0
Lipid particle organization,0,0,0,0,0,0
LPS/IL-1 Mediated Inhibition of RXR Function,-0.816,0,0,0.365,1.043,-0.302
LPS-stimulated MAPK Signaling,1.414,0,0.302,2.887,2.117,-2.668
LXR/RXR Activation,-0.816,1,0,-1.768,-1.46,2.324
Lymphotoxin β Receptor Signaling,2.236,0,-0.333,1.291,2.111,-2.333
Lysine Degradation II,0,0,0,0,0,0
Macroautophagy,0,0,0.816,0.229,0.728,0
Macrophage Alternative Activation Signaling Pathway,3.8,-0.816,0.174,2.066,0,-3.138
Macrophage Classical Activation Signaling Pathway,3.5,-2.121,1.213,1.64,0.784,-4.025
Macropinocytosis Signaling,2.449,0,-0.707,3.9,2.828,-2.324
MAP kinase activation,0,0,0,-1,1.414,-1.134
MAPK targets/ Nuclear events mediated by MAP kinases,0,0,0,1.508,1.897,0
Maturity Onset Diabetes of Young (MODY) Signaling,0,0,0,0,0,0
Mechanisms of Viral Exit from Host Cells,0,0,0,0,0,0
Melanocyte Development and Pigmentation Signaling,2.236,0,0,3.413,2.611,-1.604
Melanoma Signaling,2,0,-0.816,2.84,2.183,-1
Melatonin Signaling,0,0,1.342,0.816,0.229,-0.707
Metabolism of amine-derived hormones,0,0,1.342,0,-2,0
Metabolism of Angiotensinogen to Angiotensins,0,0,0,0.333,-0.707,0
Metabolism of folate and pterines,0,0,0,1,0,0
Metabolism of nitric oxide: NOS3 activation and regulation,0,0,0,1.134,0.816,0
Metabolism of porphyrins,0,0,0,2.121,2,1.342
Metabolism of steroid hormones,0,2.236,2.449,-1,-1,0
Metallothioneins bind metals,-2.828,2.828,2.449,0,0,0
MHC class II antigen presentation,2.53,1.342,2.887,2.268,0.192,-3.207
Microautophagy Signaling Pathway,0,0,1.414,1.671,2.2,2.236
MicroRNA Biogenesis Signaling Pathway,2.646,0,1.528,2.1,2.654,-1
MIF Regulation of Innate Immunity,0.816,0,2.121,0.905,-0.535,-2.828
MIF-mediated Glucocorticoid Regulation,2,0,1.633,1.265,-0.905,-2.449
Mineralocorticoid Biosynthesis,0,0,0,0,0,0
Miscellaneous transport and binding events,0,0,0,2.121,1.667,0
Mitochondrial biogenesis,0,0,1.134,0.2,0.853,0
Mitochondrial Dysfunction,0.277,-1.897,-2.722,2.8,0.577,-1.347
Mitotic Metaphase and Anaphase,0,0,3.3,2.496,4.662,-3.441
Mitotic Prometaphase,1.134,0.816,3.266,0.64,4.158,-3.441
Mitotic Prophase,0,0,0.816,0.962,3.024,1
Mitotic Roles of Polo-Like Kinase,0,0,1,-0.632,0.632,-0.816
Mitotic Telophase/Cytokinesis,0,0,0,0.447,1.89,0
Molecular Mechanisms of Cancer,9.791,-2.921,3.058,5.942,0.605,-7.425
Mouse Embryonic Stem Cell Pluripotency,2.236,0,1.213,1.808,1.667,-2.183
mRNA Editing,0,0,0,0,0,0
MSP-RON Signaling in Cancer Cells Pathway,1.155,0,2.694,2.111,0.632,-3.128
MSP-RON Signaling in Macrophages Pathway,0,0,2.683,0.493,0.73,-0.243
MSP-RON Signaling Pathway,0,0,0,0,0,0
mTOR Signaling,2.333,2,-0.577,2.064,1.206,-1.886
Multiple Sclerosis Signaling Pathway,4.146,-2.333,1.3,2,1,-3.78
MYC Mediated Apoptosis Signaling,0,0,0,0.258,0.302,-0.378
MyD88 cascade initiated on plasma membrane,0,0,0,1.342,1.667,0
MyD88 dependent cascade initiated on endosome,0,0,0,1.89,1.732,0
MyD88:MAL(TIRAP) cascade initiated on plasma membrane,0,0,-1,2.668,1.698,0
MyD88-independent TLR4 cascade,0,0,0,1.897,2.84,0
Myelination Signaling Pathway,3.024,-1,4.41,1.238,0.101,-4.33
Myogenesis,0,0,0,0.905,0.333,0
Myo-inositol Biosynthesis,0,0,0,0,0,0
NAD Signaling Pathway,2.333,-1,0.5,0.48,2.401,-0.535
NAFLD Signaling Pathway,1.147,-0.333,2,0.943,0.132,-3.413
Natural Killer Cell Signaling,3.273,0,1.347,2.462,0.14,-4.619
NCAM signaling for neurite out-growth,3.5,0,3.606,-1.091,-2.132,-3.051
Necroptosis Signaling Pathway,2.646,-2,2.324,1.333,0.48,-2.524
Neddylation,0.905,0,2.668,0.75,2.689,-0.333
Netrin Signaling,1.387,1,2.4,1.155,1.206,-1.964
Netrin-1 signaling,2.236,0,0.816,0.535,-0.277,-3.162
Neuregulin Signaling,-1,0,1.342,1.964,2.524,-1.941
Neurexins and neuroligins,1.89,0,1.265,-0.229,-0.655,0
Neuroinflammation Signaling Pathway,3.889,-2.714,0,4.096,2.101,-3.812
Neuropathic Pain Signaling in Dorsal Horn Neurons,2.887,0,1,2.197,1.177,-2.84
Neurotransmitter release cycle,0,0,2.333,0.277,-0.258,-1
Neurotransmitter uptake and metabolism In glial cells,0,0,0,0,0,0
Neurotrophin/TRK Signaling,0.447,0,0.632,2.683,2.6,-1.508
Neurovascular Coupling Signaling Pathway,4.49,-3.051,1,2.54,0.816,-3.128
Neutrophil degranulation,7.5,-3.207,1.905,8.056,-1.026,-7.506
Neutrophil Extracellular Trap Signaling Pathway,2.023,-1.387,-0.944,1.473,1.207,-2.216
NF-κB Activation by Viruses,2.828,0,0,3.657,2.353,-3.153
NGF Signaling,2.449,0,1.155,1.029,1.206,-2.683
NGF-stimulated transcription,-1,0,3.464,0.577,0.378,0
Nitric Oxide Signaling in the Cardiovascular System,2.887,0,-0.229,3.087,1.732,-1.387
NLR signaling pathways,2,0,2.449,1.043,0,-2.496
nNOS Signaling in Neurons,0,0,0,-0.447,-0.447,0
nNOS Signaling in Skeletal Muscle Cells,0,0,0,0,0,0
NOD1/2 Signaling Pathway,2,-1.414,2.132,1.234,0.493,-3.922
Non-Small Cell Lung Cancer Signaling,2.236,0,-0.707,3.441,2.524,-1.732
Noradrenaline and Adrenaline Degradation,0,0,0,1.342,0,-0.378
Notch Signaling,0,0,0.378,0,0,0
NR1H2 and NR1H3-mediated signaling,0,0,1.134,0,-1.069,0
NRF2-mediated Oxidative Stress Response,1.342,0,2.111,1.512,0.894,0
Nucleotide catabolism,0,0,0,-0.302,0.707,-1
OAS antiviral response,0,0,0,2,0,0
Oleate Biosynthesis II (Animals),0,0,-1.342,0,0,0
O-linked glycosylation,4.472,-2.646,3.545,-0.354,-0.186,-3.051
Oncostatin M Signaling,0,0,1.342,1.604,1.387,-1.667
Opioid Signaling Pathway,2.6,0,0.5,2.621,1.912,-1.461
Opioid Signalling,2.828,0,0.816,3.413,0.539,-2.333
Orexin Signaling Pathway,3.13,0.333,2.263,0.688,1.152,-2.746
Osteoarthritis Pathway,3.606,-0.378,1.667,1.109,-1.021,-3.411
Other interleukin signaling,2,0,2.236,-0.447,-2.449,-2
Ovarian Cancer Signaling,2.236,0,1.807,1.8,1,-2.138
Oxidative Phosphorylation,0,2.236,3,-5.048,-1.291,2.236
Oxytocin in Brain Signaling Pathway,2.711,0,2.191,1.89,1.05,-1.134
Oxytocin in Spinal Neurons Signaling Pathway,0,0,-0.447,0.832,0.535,0
Oxytocin Signaling Pathway,2.982,-0.535,4.143,2.269,0.816,-2.887
P2Y Purigenic Receptor Signaling Pathway,1.732,0,1.291,2.03,0.822,-2.683
p38 MAPK Signaling,2.236,0,1.387,0.962,1.091,-2.138
p53 Signaling,0,0,1.5,-0.816,-0.577,0.632
p75 NTR receptor-mediated signalling,3.051,0,3.207,-1.414,-1.616,-2.673
PAK Signaling,3,-1,1.147,2.121,1.976,-2.5
Pancreatic Adenocarcinoma Signaling,2.449,0,1.291,1.732,0,-3
Pancreatic Secretion Signaling Pathway,3.128,0,4.003,0.768,0.124,-3.528
Parkinson's Signaling,0,0,0,0,0,0
Pathogen Induced Cytokine Storm Signaling Pathway,5.774,-2.138,3.862,4.271,-0.508,-6.862
Pathogenesis of Multiple Sclerosis,0,0,0,0,0,0
Paxillin Signaling,2.646,0,0.535,1.961,2.2,-2.496
PCP (Planar Cell Polarity) Pathway,0,0,3.207,-0.302,0.832,-2.111
"PD-1, PD-L1 cancer immunotherapy pathway",-2.121,0,0.333,-1.225,-0.688,2.524
PDGF Signaling,1.134,0,1.155,1.414,2.646,-2.5
PEDF Signaling,1.342,0,0.302,1.8,1.347,-2.138
Peptide hormone biosynthesis,0,0,0,0,0,0
PFKFB4 Signaling Pathway,1.342,0,0,1.604,0.577,-1.633
Phagosome Formation,10.302,-2.502,2.074,7.133,0.889,-8.224
Phase I - Functionalization of compounds,0,2,0.905,1.091,-0.535,1.604
Phase II - Conjugation of compounds,0,0,-1.134,2.711,1.732,2.121
Phospholipases,3,0,1.633,0.535,-1.069,-2.121
PI Metabolism,2,0,0,1.569,1.732,-1.667
PI3K Cascade,0,0,1,0.728,1.732,0
PI3K/AKT Signaling,2.449,0,-0.302,2.832,2.082,-1.069
PIP3 activates AKT signaling,1.265,-1,1.342,2.021,2,-2.5
"Plasma lipoprotein assembly, remodeling, and clearance",2.449,0.447,0.277,-0.186,-1.225,1.414
Platelet Adhesion to exposed collagen,2.449,0,1.633,1.633,0,0
Platelet Aggregation (Plug Formation),2.449,0,2.121,0,-2,-2
Platelet homeostasis,3.464,0,0.832,1.372,0.756,-3.464
Polyamine Regulation in Colon Cancer,0,0,2.449,-0.832,-1,0
Post-translational protein phosphorylation,1.807,-2,3.411,0.539,-2.043,-2.668
Potassium Channels,4,-1.134,1.706,0.756,-0.853,-1.265
PPAR Signaling,0.816,0,-1.387,-1.095,-1.177,1.807
PPARα/RXRα Activation,0.302,-0.447,-0.258,-1.067,-2.359,0.447
Prednisone ADME,0,0,0,1,0,0
Presynaptic depolarization and calcium channel opening,0,0,0,0,-0.447,0
Primary Immunodeficiency Signaling,0,0,0,0,0,0
Processing of Capped Intron-Containing Pre-mRNA,0,0,4.379,-4.565,1.313,0
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages,2.357,0,0.626,0.535,-0.438,-3
Prolactin Signaling,0.816,0,-0.905,3.157,2.646,-2.5
Prostanoid Biosynthesis,0,0,0,2,0,0
Prostate Cancer Signaling,0,0,0,0,0,0
Protein folding,2.121,0,1.508,1.3,0,-2.121
Protein Kinase A Signaling,2.449,-1,0,2.36,1.238,-1
Protein Sorting Signaling Pathway,2.121,0,0.728,3.394,2.48,-1.147
Protein Ubiquitination Pathway,0,0,0,0,0,0
PTEN Signaling,-3.606,0,0.243,-2.777,-1.581,2
Pulmonary Fibrosis Idiopathic Signaling Pathway,4.529,-1.604,5.815,1.818,0.198,-6.303
Pulmonary Healing Signaling Pathway,3.771,-0.378,5.096,2.673,0.267,-4.841
Purine Nucleotides Degradation II (Aerobic),2,0,0,-0.447,0,0
Purine Ribonucleosides Degradation to Ribose-1-phosphate,0,0,0,0,0,0
Pyridoxal 5'-phosphate Salvage Pathway,0,0,1,0.218,0,-1.89
Pyrimidine Ribonucleotides De Novo Biosynthesis,0,0,1.633,-0.277,-0.333,0
Pyrimidine Ribonucleotides Interconversion,0,0,1.342,0,-0.333,0
Pyroptosis,0,0,0,1.89,1,-2.236
Pyroptosis Signaling Pathway,3.162,0,-0.302,2.402,0,-2.84
RAB GEFs exchange GTP for GDP on RABs,2.449,0,0.632,1.177,0.87,0
RAB geranylgeranylation,2.646,0,1,1.46,2,-0.816
RAC Signaling,3.207,0,0,2.92,1.859,-2.065
RAF/MAP kinase cascade,2.6,-2.449,4.542,1.709,0.246,-3.78
RAN Signaling,0,0,0,1,2.646,0
RANK Signaling in Osteoclasts,1.134,0,1.155,1.043,1.671,-2.183
Rap1 signalling,0,0,0,0.707,0.333,0
RAR Activation,1.234,0.632,1.953,2.61,1.929,-0.762
Receptor-type tyrosine-protein phosphatases,0,0,0.333,0.816,0,0
Reelin Signaling in Neurons,3.051,0,0,1.896,0.324,-2.711
Regulation of Actin-based Motility by Rho,2.53,0,3.153,-0.186,-0.816,-2.714
Regulation of Cellular Mechanics by Calpain Protease,2,0,1.414,1.5,0.5,-1.134
Regulation of cholesterol biosynthesis by SREBP (SREBF),0,0,0,1.633,1.89,0
Regulation of eIF4 and p70S6K Signaling,2.449,0,-1.265,2.132,2.294,-0.905
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by IGFBPs,2,-2.449,3.53,0.667,-2.667,-2.683
Regulation of lipid metabolism by PPARalpha,0,0,0,1,2.646,-0.447
Regulation of the Epithelial Mesenchymal Transition by Growth Factors Pathway,1.291,-1.134,2.117,2.38,1.838,-3.651
Regulation of the Epithelial Mesenchymal Transition in Development Pathway,0,0,3.638,-0.229,-0.943,-3.464
Regulation of the Epithelial-Mesenchymal Transition Pathway,0,0,0,0,0,0
Regulation of TLR by endogenous ligand,0,0,-2,3.317,1.89,0
Regulation of TP53 Activity through Phosphorylation,0,0,2.121,0,2.711,-1.342
Relaxin Signaling,1.414,0,0.277,3.272,1.46,-1.387
Renal Cell Carcinoma Signaling,0.447,0,0,3.3,2.985,-0.632
Renin-Angiotensin Signaling,1.667,0,1.291,3,2.137,-2.828
Response to elevated platelet cytosolic Ca2+,4,-2.236,1.46,3.571,0,-2.132
RET signaling,1.342,0,0.447,0.243,-0.471,-2.449
Retinoid metabolism and transport,3,0,1,0.832,-1.732,-2.121
RHO GTPase cycle,5.857,0,3.732,1.971,1.058,-5.196
RHO GTPases activate CIT,0,0,0,0,-0.378,0
RHO GTPases Activate Formins,0.447,0,3.207,1.183,2.897,-4
RHO GTPases activate KTN1,0,0,0,0,-0.447,0
RHO GTPases Activate NADPH Oxidases,2.646,0,1,0.905,-2.449,-2.236
RHO GTPases activate PKNs,0,0,2,1,-0.302,0
RHO GTPases Activate Rhotekin and Rhophilins,0,0,0,-1.342,0,0
RHO GTPases Activate ROCKs,0,0,0,0,-0.378,0
RHO GTPases Activate WASPs and WAVEs,0,0,0,3.051,0.707,-2.236
RHOA Signaling,1.134,0,2.858,0.926,0.16,-1.291
RHOGDI Signaling,-3.153,0.447,-4.017,0,0.801,3.545
Ribonucleotide Reductase Signaling Pathway,1.265,0,2.558,1.234,1.508,-3.411
RNA polymerase II transcribes snRNA genes,0,0,2,-1.732,0.218,0
RNA Polymerase II Transcription,0,0,2.714,-1.809,1.177,0
ROBO SLIT Signaling Pathway,1,-1.342,-0.6,-1.333,-1.616,0.471
Role of BRCA1 in DNA Damage Response,0,0,1.342,-0.302,1.387,0
Role of Chondrocytes in Rheumatoid Arthritis Signaling Pathway,0.832,-1.414,2.887,2.082,1.915,-3.128
Role of IL-17A in Arthritis,0,0,0,0,0,0
Role of IL-17A in Psoriasis,0,0,2.449,0,0,0
Role of IL-17F in Allergic Inflammatory Airway Diseases,0,0,2.449,1.414,0.905,-1
Role of JAK family kinases in IL-6-type Cytokine Signaling,0,0,2.837,-0.816,-0.229,-3.357
Role of JAK1 and JAK3 in γc Cytokine Signaling,0,0,0,0,0,0
Role of JAK2 in Hormone-like Cytokine Signaling,-1,0,0.5,1.606,1.147,-1
"Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis",0,0,0,0,0,0
Role of MAPK Signaling in Inhibiting the Pathogenesis of Influenza,1.414,-2,2.111,1.706,0.894,-2.111
Role of MAPK Signaling in Promoting the Pathogenesis of Influenza,1.414,0,3.051,0.73,0.557,-1.941
Role of MAPK Signaling in the Pathogenesis of Influenza,0,0,0,0,0,0
Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency,2,0,-0.632,2.837,2.837,-1.732
Role of NFAT in Cardiac Hypertrophy,3,0,0.816,1.838,1.26,-3.024
Role of Osteoblasts in Rheumatoid Arthritis Signaling Pathway,1.877,-2.121,1.852,-0.855,-0.944,-1.761
"Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis",0,0,0,0,0,0
Role of Osteoclasts in Rheumatoid Arthritis Signaling Pathway,5.729,-1.265,4.061,2.157,-0.229,-5.25
Role of p14/p19ARF in Tumor Suppression,-2,0,1.342,-1.89,-1.265,1.342
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses,2.887,0,-1.155,4.004,1.961,-3.5
Role of PI3K/AKT Signaling in the Pathogenesis of Influenza,0,0,-1.134,2.84,1.291,-0.905
Role of PKR in Interferon Induction and Antiviral Response,0,0,1.897,0.73,2.558,-2.183
Role of Tissue Factor in Cancer,2.711,-1.134,2.137,3.939,2.216,-3.202
RORA activates gene expression,0,0,0,0.447,0,0
rRNA processing,0,0,0,0,0,0
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),2,0,0,0,0,-1
S100 Family Signaling Pathway,8.119,-2.558,3.182,4.627,-0.08,-7.633
Salvage Pathways of Pyrimidine Ribonucleotides,2.449,-0.447,2.121,-0.186,-0.577,-2.111
Semaphorin interactions,2.714,0,0.816,1,-1.606,-3.207
Semaphorin Neuronal Repulsive Signaling Pathway,0.426,1.342,2.6,-1.286,-1.732,-0.816
Semaphorin Signaling in Neurons,0,0,0,0,0,0
Senescence Pathway,1.279,0.378,2.556,3.394,1.565,-1.715
Sensory processing of sound by inner hair cells of the cochlea,1,1.414,2.5,-1.3,-2.132,0
Sensory processing of sound by outer hair cells of the cochlea,0,1.414,2.138,-2.041,-1.941,0
Serine biosynthesis,0,0,0,1.342,0,0
Serotonin Receptor Signaling,5.126,-1.604,2.689,4.7,1.311,-5.25
Sertoli Cell-Germ Cell Junction Signaling Pathway (Enhanced),0.209,-1,0.149,1.254,1.068,-1.543
Sertoli Cell-Sertoli Cell Junction Signaling,2.449,-0.333,2.941,0.126,-0.122,-2.592
Signal amplification,2.236,0,-0.447,2.673,1.069,-1
Signal regulatory protein family interactions,0,0,0,2.236,1,-2.236
Signaling by Activin,0,0,0,0,0,1
Signaling by ALK,0,0,0.447,1.897,1.134,-2.449
Signaling by BMP,0,0,0,2.121,1.155,0
Signaling by CSF1 (M-CSF) in myeloid cells,2.236,0,-1,2.84,2.111,-2.121
Signaling by CSF3 (G-CSF),0,0,0,2.138,1.265,-2.236
Signaling by EGFR,0,0,0,1.508,2,0
Signaling by ERBB2,0,0,0.816,0.832,2.84,-1.342
Signaling by ERBB4,0,0,0.707,1.941,2.324,0
Signaling by Erythropoietin,0.447,0,0,2.333,2.111,-2.236
Signaling by FGFR1,0,0,1.134,2,2.5,0
Signaling by FGFR3,0,0,1.414,1.069,2.714,0
Signaling by FGFR4,0,0,0.816,1.604,2.496,0
Signaling by Hippo,0,0,0,2,1.89,0
Signaling by Leptin,0,0,0,1.633,1,0
Signaling by MET,3.051,-0.447,2.668,0.577,0.6,-3.051
Signaling by MST1,0,0,0,-2.236,0,0
Signaling by NOTCH1,2,0,2.309,-0.209,-0.392,-1.667
Signaling by NOTCH2,0,0,1.633,1.155,0,-2
Signaling by NOTCH3,2.236,0,2.828,-0.243,-1,-1.897
Signaling by NTRK1 (TRKA),0.816,0,1.414,1.8,0.853,-1.89
Signaling by NTRK2 (TRKB),0,0,0.447,1.134,2.333,0
Signaling by NTRK3 (TRKC),0,0,0,0.378,1.633,0
Signaling by PDGF,3.317,-2.236,2.53,1.091,1.414,-3.873
Signaling by Rho Family GTPases,3.545,-0.816,3.618,0.492,-0.775,-3.888
Signaling by SCF-KIT,0,0,0.447,2.837,1.698,-2.333
Signaling by TGF-beta Receptor Complex,2.828,-2,1.414,1.213,1.069,-1.89
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0,0,0,1.633,2.121,0
Signaling by VEGF,4,0,2,2.16,-0.392,-3.207
Sirtuin Signaling Pathway,0,-0.333,0.192,1.807,0.944,0.302
Small Cell Lung Cancer Signaling,2.236,0,-0.816,0.728,1.5,-1.897
SNARE Signaling Pathway,2.53,0.707,3.578,0.343,-0.48,-1
Sperm Motility,3.606,0,3,1.265,0.707,-3.051
Spermidine Biosynthesis I,0,0,0,0,0,0
Sphingolipid metabolism,2,0,1,1.3,0.688,0
Sphingomyelin Metabolism,0,0,0,0,0,0
Sphingosine-1-phosphate Signaling,1.732,0,0.905,1.061,1,-1.342
SPINK1 General Cancer Pathway,2.887,-2.828,-1.291,2.683,2.683,-0.577
STAT3 Pathway,3,0,0.243,1.677,0.493,-1.886
Striated Muscle Contraction,0,0,3.873,0.577,-0.707,0
SUMOylation of DNA damage response and repair proteins,0,0,1,0,3.545,0
SUMOylation of DNA methylation proteins,0,0,0,-1.134,0,0
SUMOylation of immune response proteins,0,0,0,0,0,0
Sumoylation Pathway,-1.633,0,0,0.243,0.655,0
Superpathway of Cholesterol Biosynthesis,0,2,-2,-0.632,2.646,0
Superpathway of Citrulline Metabolism,0,0,0,0,0.816,0
"Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism",0,0,0,-1.134,0.707,0
Superpathway of Inositol Phosphate Compounds,2.309,0,3.402,0.258,1.387,-2.041
Superpathway of Melatonin Degradation,0,0,-1.633,1.886,1.134,1.667
Surfactant metabolism,2,0,1,0.816,0,-2
Synaptic Long Term Depression,3.638,-1,2,2.1,0.438,-1.789
Synaptic Long Term Potentiation,3.162,0,1.265,1.677,0.333,-1.732
Synaptogenesis Signaling Pathway,4.707,-2.714,2.722,2.982,-0.221,-4.11
Syndecan interactions,3,0,1.342,2.111,0,-1.89
TCR signaling,1.342,0,1.633,2.353,1.528,-3.3
Telomerase Signaling,2.449,0,-1,3.53,1.789,-1.604
TGF-β Signaling,0,0,1.134,1.886,2.6,0
Th1 and Th2 Activation Pathway,0,0,0,0,0,0
Th1 Pathway,3.153,0,0,4.012,0,-4.747
Th2 Pathway,2.065,0,0.426,1.443,-0.2,-2.414
The citric acid (TCA) cycle and respiratory electron transport,0,0,0,1.886,1.604,1.414
Thrombin Signaling,2.84,0,1.147,2.219,1.131,-2.646
Thrombin signalling through proteinase activated receptors (PARs),2,0,-1,2.496,0.333,0
Thrombopoietin Signaling,0.707,0,-0.333,3.838,2.985,-2.324
Thyroid Cancer Signaling,0.707,0,1.698,2.4,1,-1.604
Tight Junction Signaling,0,0,0,0,0,0
TNF signaling,0,0,2.236,-0.728,0.943,-0.447
TNFR1 Signaling,0,0,2,-1,-0.577,-2
TNFR2 Signaling,0,0,2,-0.816,0,-2.236
TNFs bind their physiological receptors,0,0,2.236,0.632,0.378,-2.646
Toll Like Receptor 3 (TLR3) Cascade,0,0,0,1.414,2.496,0
Toll-like Receptor Cascades,2.828,0,-2.646,3.5,1.897,-2
Toll-like Receptor Signaling,0,0,0,2.183,1.604,-2
TP53 Regulates Transcription of Cell Death Genes,2,0,1.633,0.302,0.832,0
TR/RXR Activation,2.333,0,1.043,1.257,1.183,-2.324
Trafficking and processing of endosomal TLR,2,0,0,1.633,0,0
Transcription from mitochondrial promoters,0,0,0,0,0,0
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0,0,1,1.732,2.138,-2
Transcriptional regulation by RUNX2,0,0,1.89,1.069,0.302,-2.333
Transcriptional regulation of granulopoiesis,0,0,2.236,-0.707,-0.632,-1.414
Transcriptional regulation of testis differentiation,0,0,2,0,0,0
Transcriptional regulation of white adipocyte differentiation,0.816,0,0.905,0,1.633,0
Transcriptional Regulatory Network in Embryonic Stem Cells,2.828,0,1.569,1.677,1.732,-1.8
trans-Golgi Network Vesicle Budding,-1,0,0.378,1.8,2.183,0
Translocation of SLC2A4 (GLUT4) to the plasma membrane,0,1,0,3.153,1.606,-1
Transport of inorganic cations/anions and amino acids/oligopeptides,3.162,-1,1.886,1.414,0.928,-2.5
"Transport of vitamins, nucleosides, and related molecules",0,0,1,-0.632,-0.577,0
Trehalose Degradation II (Trehalase),1,0,0,0,0,0
TREM1 Signaling,3.051,0,0,4.707,0.775,-4.359
Triacylglycerol Biosynthesis,0,0,1.508,0.258,0.277,-0.707
Triglyceride metabolism,0,0,1,2.309,1.265,0
tRNA Splicing,1.89,0,0.447,1.5,2.5,0
Tumor Microenvironment Pathway,3.657,-2.53,3.703,2.885,0.885,-4
Tumoricidal Function of Hepatic Natural Killer Cells,0,0,0,0,0,0
TWEAK Signaling,0,0,0,-0.632,-1.265,-0.447
Type II Diabetes Mellitus Signaling,2.121,0,-1.265,1.8,0.853,-3.3
UDP-D-xylose and UDP-D-glucuronate Biosynthesis,0,0,0,0,0,0
UDP-N-acetyl-D-galactosamine Biosynthesis II,1,0,0,0,1,0
UVA-Induced MAPK Signaling,2.236,0,0,2.4,1.633,-2.111
UVB-Induced MAPK Signaling,0.816,0,0,2.065,2.668,-1.897
UVC-Induced MAPK Signaling,0,0,2.236,1.291,1.069,-1.667
Valine Degradation I,0,0,-1.342,1.633,1.342,2.449
Vasopressin regulates renal water homeostasis via Aquaporins,0,0,1,2.324,0.632,-2
VDR/RXR Activation,0,0,-0.447,1.155,-0.707,0
VEGF Family Ligand-Receptor Interactions,2.714,0,1.213,2.887,1.347,-2.668
VEGF Signaling,2.121,0,1.213,2.502,1.4,-1.941
Virus Entry via Endocytic Pathways,0,0,0,0,0,0
White Adipose Tissue Browning Pathway,2.121,-1,2.138,0.469,0.174,-0.832
WNK Renal Signaling Pathway,1.134,0,0.775,2.353,2.683,-1.155
WNT ligand biogenesis and trafficking,0,0,2.449,1.633,1.342,-2
WNT/Ca+ pathway,1.342,0,2.236,-0.832,-0.688,-2.449
WNT/β-catenin Signaling,0.707,0,0.577,-0.169,-0.16,-0.426
Wound Healing Signaling Pathway,2.959,-1.387,4.18,0.593,0.126,-4.041
XBP1(S) activates chaperone genes,0,0,2,-1.387,-1.069,0
Xenobiotic Metabolism AHR Signaling Pathway,0,0,-0.333,1.698,0.775,-0.632
Xenobiotic Metabolism CAR Signaling Pathway,2.496,0.447,-0.243,1.286,1.347,0.209
Xenobiotic Metabolism General Signaling Pathway,3,0,1.147,1.18,1.183,-1.606
Xenobiotic Metabolism PXR Signaling Pathway,1.604,0,-0.229,1.192,1.461,0.229
Xenobiotic Metabolism Signaling,0,0,0,0,0,0
YAP1- and WWTR1 (TAZ)-stimulated gene expression,0,0,0,1.342,0.816,0
Zymosterol Biosynthesis,0,0,0,0,0,0
α-Adrenergic Signaling,0,0,1.414,2.294,1.807,-1.265
β-alanine Degradation I,0,0,0,0,0,0
γ-glutamyl Cycle,0,0,0,-0.816,-0.378,0
